Isis sees way to Phase III with triglyceride lowerer
This article was originally published in Scrip
Isis Pharmaceuticals has released positive Phase II data for an investigational treatment, ISIS-APOCIII, for the ultra-orphan disease, familial chylomicronemia syndrome (FCS).
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.